217 related articles for article (PubMed ID: 27259012)
21. Aberrant keratin 7 and 20 expression in triple-negative carcinoma of the breast.
Kuroda H; Imai Y; Yamagishi H; Ueda Y; Kuroso K; Oishi Y; Ohashi H; Yamashita A; Yashiro Y; Fukushima H
Ann Diagn Pathol; 2016 Feb; 20():36-9. PubMed ID: 26670478
[TBL] [Abstract][Full Text] [Related]
22. Avoidance and Period-Shortening of Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer in Stages I and II: Importance of Ki-67 Labeling Index and the Recognition of Apocrine-Type Lesions.
Kubouchi K; Shimada K; Yokoe T; Tsutsumi Y
Technol Cancer Res Treat; 2020; 19():1533033820943246. PubMed ID: 32677589
[TBL] [Abstract][Full Text] [Related]
23. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
Abd-Elazeem MA; Abd-Elazeem MA
Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor expression in triple negative breast carcinoma and its association with the clinicopathological parameters.
Teoh PY; Tan GC; Mahsin H; Wong YP
Malays J Pathol; 2019 Aug; 41(2):125-132. PubMed ID: 31427547
[TBL] [Abstract][Full Text] [Related]
25. IMP3, a proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast.
Vranic S; Gurjeva O; Frkovic-Grazio S; Palazzo J; Tawfik O; Gatalica Z
Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):413-6. PubMed ID: 21436679
[TBL] [Abstract][Full Text] [Related]
26. Mixed Invasive Apocrine Papillary/Micropapillary Carcinoma of the Breast: Another Brick in the Triple-Negative Wall.
Cima L; Mirabassi N; Sartori C; Carbone FG; Morelli L; Cserni G; Barbareschi M
Int J Surg Pathol; 2021 Jun; 29(4):420-426. PubMed ID: 32909476
[TBL] [Abstract][Full Text] [Related]
27. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
28. Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy.
Montagna E; Cancello G; Pagan E; Bagnardi V; Munzone E; Dellapasqua S; Viale G; Mazzarol G; Veronesi P; Galimberti V; Santomauro G; Colleoni M
Breast; 2020 Oct; 53():138-142. PubMed ID: 32795829
[TBL] [Abstract][Full Text] [Related]
29. Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm.
Jongen L; Paridaens R; Floris G; Wildiers H; Neven P
Breast Cancer Res Treat; 2016 Feb; 155(3):603-7. PubMed ID: 26868122
[TBL] [Abstract][Full Text] [Related]
30. Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior.
Schwartz CJ; Ruiz J; Bean GR; Sirohi D; Joseph NM; Hosfield EM; Jacobs TW; Mukhtar RA; Chen YY; Krings G
Mod Pathol; 2023 May; 36(5):100125. PubMed ID: 36870308
[TBL] [Abstract][Full Text] [Related]
31. Apocrine Variant of Pleomorphic Lobular Carcinoma In Situ: Further Clinical, Histopathologic, Immunohistochemical, and Molecular Characterization of an Emerging Entity.
Zhong E; Solomon JP; Cheng E; Baum J; Song W; Hoda SA
Am J Surg Pathol; 2020 Aug; 44(8):1092-1103. PubMed ID: 32317606
[TBL] [Abstract][Full Text] [Related]
32. Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer.
Saridakis A; Berger ER; Harigopal M; Park T; Horowitz N; Le Blanc J; Zanieski G; Chagpar A; Greenup R; Golshan M; Lannin DR
Ann Surg Oncol; 2021 Oct; 28(10):5610-5616. PubMed ID: 34426884
[TBL] [Abstract][Full Text] [Related]
33. Apocrine carcinoma of the breast.
Yamazaki M; Nagata Y; Monji S; Shigematsu Y; Baba T; Shimokawa H; Uramoto H; Yamada S; Hanagiri T; Tanaka F
J UOEH; 2011 Dec; 33(4):293-301. PubMed ID: 22259834
[TBL] [Abstract][Full Text] [Related]
34. 15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma.
Celis JE; Gromov P; Cabezón T; Moreira JM; Friis E; Jirström K; Llombart-Bosch A; Timmermans-Wielenga V; Rank F; Gromova I
Mol Cell Proteomics; 2008 Oct; 7(10):1795-809. PubMed ID: 18632593
[TBL] [Abstract][Full Text] [Related]
35. ER-α36, a novel isoform of ER-α66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast.
Vranic S; Gatalica Z; Deng H; Frkovic-Grazio S; Lee LM; Gurjeva O; Wang ZY
J Clin Pathol; 2011 Jan; 64(1):54-7. PubMed ID: 21045236
[TBL] [Abstract][Full Text] [Related]
36. Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer.
Thike AA; Yong-Zheng Chong L; Cheok PY; Li HH; Wai-Cheong Yip G; Huat Bay B; Tse GM; Iqbal J; Tan PH
Mod Pathol; 2014 Mar; 27(3):352-60. PubMed ID: 23929266
[TBL] [Abstract][Full Text] [Related]
37. Heat shock protein 27 and gross cystic disease fluid protein 15 play critical roles in molecular apocrine breast cancer.
Liu X; Feng C; Liu J; Zhao L; Liu J; Zhang W; Liu N; Niu Y
Tumour Biol; 2016 Jun; 37(6):8027-36. PubMed ID: 26711786
[TBL] [Abstract][Full Text] [Related]
38. Triple-negative apocrine carcinoma: A rare pathologic subtype with a better prognosis than other triple-negative breast cancers.
Arciero CA; Diehl AH; Liu Y; Sun Q; Gillespie T; Li X; Subhedar P
J Surg Oncol; 2020 Nov; 122(6):1232-1239. PubMed ID: 32668059
[TBL] [Abstract][Full Text] [Related]
39. Cutaneous and mammary apocrine carcinomas have different immunoprofiles.
Piris A; Peng Y; Boussahmain C; Essary LR; Gudewicz TM; Hoang MP
Hum Pathol; 2014 Feb; 45(2):320-6. PubMed ID: 24342430
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological characteristics and prognostic marker of triple-negative breast cancer in older women.
Honma N; Ogata H; Yamada A; Matsuda Y; Kontani K; Miyashita M; Arai T; Sasaki E; Shibuya K; Mikami T; Sawaki M
Hum Pathol; 2021 May; 111():10-20. PubMed ID: 33548251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
